Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
1.
Front Mol Biosci ; 10: 1229760, 2023.
Artigo em Inglês | MEDLINE | ID: mdl-37520325

RESUMO

Leukemic cells acquire complex and often multifactorial mechanisms of resistance to treatment, including various metabolic alterations. Although the use of metabolic modulators has been proposed for several decades, their use in clinical practice has not been established. Natural products, the so-called botanical drugs, are capable of regulating tumor metabolism, particularly in hematopoietic tumors, which could partly explain the biological activity attributed to them for a long time. This review addresses the most recent findings relating to metabolic reprogramming-Mainly in the glycolytic pathway and mitochondrial activity-Of leukemic cells and its role in the generation of resistance to conventional treatments, the modulation of the tumor microenvironment, and the evasion of immune response. In turn, it describes how the modulation of metabolism by plant-derived extracts can counteract resistance to chemotherapy in this tumor model and contribute to the activation of the antitumor immune system.

2.
Cancers (Basel) ; 14(24)2022 Dec 10.
Artigo em Inglês | MEDLINE | ID: mdl-36551566

RESUMO

Despite the advances in understanding the biology of hematologic neoplasms which has resulted in the approval of new drugs, the therapeutic options are still scarce for relapsed/refractory patients. Eribulin is a unique microtubule inhibitor that is currently being used in the therapy for metastatic breast cancer and soft tissue tumors. Here, we uncover eribulin's cellular and molecular effects in a molecularly heterogeneous panel of hematologic neoplasms. Eribulin reduced cell viability and clonogenicity and promoted apoptosis and cell cycle arrest. The minimal effects of eribulin observed in the normal leukocytes suggested selectivity for malignant blood cells. In the molecular scenario, eribulin induces DNA damage and apoptosis markers. The ABCB1, ABCC1, p-AKT, p-NFκB, and NFκB levels were associated with responsiveness to eribulin in blood cancer cells, and a resistance eribulin-related target score was constructed. Combining eribulin with elacridar (a P-glycoprotein inhibitor), but not with PDTC (an NFkB inhibitor), increases eribulin-induced apoptosis in leukemia cells. In conclusion, our data indicate that eribulin leads to mitotic catastrophe and cell death in blood cancer cells. The expression and activation of MDR1, PI3K/AKT, and the NFκB-related targets may be biomarkers of the eribulin response, and the combined treatment of eribulin and elacridar may overcome drug resistance in these diseases.

3.
Cad. saúde colet., (Rio J.) ; 29(3): 351-365, July-Sept. 2021. tab, graf
Artigo em Português | LILACS-Express | LILACS | ID: biblio-1360319

RESUMO

Resumo Introdução A Unidade de Assistência de Alta Complexidade em Oncologia (UNACON) permite o tratamento de leucemias agudas no Acre. Objetivo Determinar o perfil clínico-epidemiológico e a sobrevida hospitalar de leucemias agudas tratadas na UNACON/Acre entre 2007 e 2014. Método É um estudo longitudinal e retrospectivo de pacientes com leucemias agudas entre 15/06/2007 e 31/12/2014, cujos prontuários médicos forneceram dados para a análise descritiva das variáveis e posterior análise de sobrevida acumulada em 1 ano e 2 anos (método Kaplan-Meier) e comparação das curvas de sobrevida (teste de log-rank). Resultados A sobrevida para leucemias mieloides agudas (LMA) foi de 30% e 32% em 1 e 2 anos, respectivamente, com pior sobrevida para pacientes masculinos, brancos, ≥ 20 anos de idade, leucometria < 20.000 células/mm3, desidrogenase lática ≥ 600 U/dl e subtipo diferente do M3. Para leucemias linfoides agudas (LLA), a sobrevida foi de 59% e 45% em 1 e 2 anos, respectivamente, com pior sobrevida para sexo feminino, ≥ 20 anos de idade e leucometria elevada. Em pacientes abaixo de 20 anos de idade com LLA, a melhor sobrevida foi observada na faixa etária de 2 a 9 anos. Conclusão Trata-se do primeiro estudo epidemiológico de sobrevida realizado no Acre para leucemias agudas com resultados coerentes com a literatura. Contudo, novas pesquisas deverão ser realizadas.


Abstract Background The High Complexity Oncology Unit (Unidade de Assistência de Alta Complexidade em Oncologia - UNACON/Acre) allowed the treatment of acute leukemias in Acre. Objective To determine the clinical-epidemiological profile and hospital survival of acute leukemias treated at UNACON/Acre between 2007 and 2014. Method This is a longitudinal, retrospective study of patients with acute leukemias between 06/15/2007 and 12/31/2014 whose medical records provided data for descriptive analysis of the variables, and subsequent analysis of 1-year and 2-year cumulative survival (Kaplan Meier method) and comparison of survival curves (log-rank test). Results The survival for acute myeloid leukemia (AML) was 30 and 32% at 1 and 2 years, respectively, with a worse survival rate for males, white, age ≥20 years, leukometry <20,000 cells/mm3, lactic dehydrogenase ≥600 U/dl and subtype different from M3. For acute lymphoid leukemias (ALL), survival was 59 and 45% at 1 and 2 years, respectively. Female gender, age ≥20 years, and high leukometry had worse survival. For patients <20 years with ALL, better survival was observed in the age group of 2-9 years. Conclusion This is the first epidemiological study of survival in Acre for acute leukemias with results consistent with the literature. However, new studies should be performed.

5.
Hematology ; 23(10): 803-809, 2018 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-30010502

RESUMO

OBJECTIVES: To demonstrate the importance of regional efforts to register features and report frequency of hematology diseases in the context of incomplete national registries. METHODS: Frequencies and salient characteristics of hematologic diseases in Northeast Mexico were documented in a reference center at a tertiary care university hospital during the decade 2005-2015. Disease categories were grouped by age, sex and diagnosis. Age group distribution followed WHO guidelines in years as children (0-17), adults (18-64) and elders (+65). RESULTS: 2406 patients were included: 1239 (51.5%) were females and 1167 (48.5%) males; F:M ratio was 1.06:1; median age was 35 years (0-95). The frequency by age group included adults, 1370 cases (56.9%), children, 695 cases (28.9%), and elderly, 341 (14.2%). Most frequent diagnoses were acute lymphoblastic leukemia (ALL) 18.2% (n = 438), anemia 15.9% (n = 383), non-Hodgkin's lymphoma (NHL) 15.7% (n = 378), immune thrombocytopenic purpura (ITP) 9.8% (n = 235) and Hodgkin's lymphoma (HL) 6.5% (n = 156). Median age for the whole cohort was 35 years; for children, was 6 years, for adults 40 and for the elderly 73. Results for ALL, anemia and ITP were comparable to high-income countries; NHL, HL and chronic myeloid leukemia presented a decade earlier. DISCUSSION: Complete, opportune reliable information on the number of cases, age and sex distribution with the potential to influence strategies for timely diagnosis and treatment options for important hematologic diseases can be accrued by regional centers. CONCLUSION: Information on hematology diseases derived of regional registries in low-middle income countries is a reasonable alternative to complement and update national registries.


Assuntos
Doenças Hematológicas/epidemiologia , Sistema de Registros , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Criança , Pré-Escolar , Feminino , Hospitais de Ensino , Humanos , Lactente , Recém-Nascido , Masculino , México/epidemiologia , Pessoa de Meia-Idade , Centros de Atenção Terciária
6.
Anticancer Res ; 36(8): 3795-802, 2016 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-27466479

RESUMO

The WT1 gene encodes a transcription factor involved in regulation of many cellular processes, including proliferation, differentiation, mRNA processing and apoptosis, besides acting as a transcription repressor of growth factors and their receptors' genes. This gene is expressed at high levels in several types of cancers, including acute leukemias. In this regard, many studies have identified WT1 protein as a tumor antigen, considered a target molecule for clinical application in human acute leukemias. Immunotherapy using WT1 antigen has been effective in stimulating immune responses against leukemic cells. Regarding adoptive immunotherapy, the use of dendritic cells (DCs) for the WT1-specific cytotoxic T cells generation proved to be efficient in the development and maintenance of immunologic cells. Therefore, these therapeutic methods, that provided enthusiasm for moving ahead, highlight several opportunities and challenges to be used in clinical practice for managing acute leukemias.


Assuntos
Antígenos de Neoplasias/genética , Imunoterapia , Leucemia/terapia , Proteínas WT1/genética , Antígenos de Neoplasias/imunologia , Apoptose/genética , Apoptose/imunologia , Diferenciação Celular/genética , Diferenciação Celular/imunologia , Proliferação de Células/genética , Células Dendríticas/imunologia , Humanos , Leucemia/genética , Leucemia/imunologia , Linfócitos T Citotóxicos/imunologia , Proteínas WT1/imunologia , Proteínas WT1/uso terapêutico
7.
Rev. cuba. hematol. inmunol. hemoter ; 31(3): 242-253, jul.-set. 2015. ilus, tab
Artigo em Espanhol | CUMED | ID: cum-66799

RESUMO

La citometría de flujo (CMF) es una técnica de avanzada, altamente sensible y automatizada, que se emplea para el inmunofenotipaje de las células normales y leucémicas. En este artículo se muestran los principales aspectos metodológicos a tener en cuenta para un mejor desarrollo e interpretación del inmunofenotipo por CMF, entre los que se encuentran: tipo, cantidad, conservación y transportación de la muestra, uso de anticoagulantes, empleo de anticuerpos monoclonales y fluorocromos, lisado de hematíes, fijación celular, así como la calibración y compensación de la auto-fluorescencia. Finalmente, se exponen las principales aplicaciones de esta metodología para definir el estado de maduración celular leucémico, clasificar las leucemias agudas en distintos subtipos inmunológicos, identificar subgrupos de mal pronóstico y detectar fenotipos aberrantes. Todo lo anterior resulta de gran utilidad para el diagnóstico de la enfermedad mínima residual que permite estratificar a los pacientes en diferentes grupos de riesgo e individualizar el tratamiento antileucémico(AU)


Flow cytometry (FCM) is an advanced, highly sensitive and automated technique used for immunophenotyping of normal and leukemic cells. The main methodological aspects to consider for better development and interpretation of immunophenotyping by FCM are shown in this article. Among them are: type, quantity, storage and transportation of the sample, use of anticoagulants, use of monoclonal antibodies and fluorochromes, erythrocyte lysate, cell attachment, calibration and auto-fluorescence compensation. Finally, the main applications of this methodology are given for defining the state of leukemic cell maturation, acute leukemias rank in different immunological subtypes, poor prognosis subgroups and to identify and detect aberrant phenotypes, which are useful for the diagnosis of minimal residual disease, allowing to stratify patients into different risk groups and thus to identify the anti-leukemic treatment(AU)


Assuntos
Humanos , Citometria de Fluxo/métodos , Metodologia como Assunto , Imunofenotipagem/métodos , Métodos Analíticos de Preparação de Amostras/métodos
8.
Rev. cuba. hematol. inmunol. hemoter ; 31(3): 242-253, jul.-set. 2015. ilus, tab
Artigo em Espanhol | LILACS | ID: lil-761912

RESUMO

La citometría de flujo (CMF) es una técnica de avanzada, altamente sensible y automatizada, que se emplea para el inmunofenotipaje de las células normales y leucémicas. En este artículo se muestran los principales aspectos metodológicos a tener en cuenta para un mejor desarrollo e interpretación del inmunofenotipo por CMF, entre los que se encuentran: tipo, cantidad, conservación y transportación de la muestra, uso de anticoagulantes, empleo de anticuerpos monoclonales y fluorocromos, lisado de hematíes, fijación celular, así como la calibración y compensación de la auto-fluorescencia. Finalmente, se exponen las principales aplicaciones de esta metodología para definir el estado de maduración celular leucémico, clasificar las leucemias agudas en distintos subtipos inmunológicos, identificar subgrupos de mal pronóstico y detectar fenotipos aberrantes. Todo lo anterior resulta de gran utilidad para el diagnóstico de la enfermedad mínima residual que permite estratificar a los pacientes en diferentes grupos de riesgo e individualizar el tratamiento antileucémico(AU)


Flow cytometry (FCM) is an advanced, highly sensitive and automated technique used for immunophenotyping of normal and leukemic cells. The main methodological aspects to consider for better development and interpretation of immunophenotyping by FCM are shown in this article. Among them are: type, quantity, storage and transportation of the sample, use of anticoagulants, use of monoclonal antibodies and fluorochromes, erythrocyte lysate, cell attachment, calibration and auto-fluorescence compensation. Finally, the main applications of this methodology are given for defining the state of leukemic cell maturation, acute leukemias rank in different immunological subtypes, poor prognosis subgroups and to identify and detect aberrant phenotypes, which are useful for the diagnosis of minimal residual disease, allowing to stratify patients into different risk groups and thus to identify the anti-leukemic treatment(AU)


Assuntos
Humanos , Masculino , Feminino , Citometria de Fluxo/métodos , Leucemia Mieloide Aguda/diagnóstico , Imunofenotipagem/métodos
9.
Medisan ; 19(4)abr.-abr. 2015. ilus, tab
Artigo em Espanhol | LILACS, CUMED | ID: lil-745148

RESUMO

Se realizó un estudio descriptivo y retrospectivo de 64 pacientes mayores de 60 años con leucemia aguda, atendidos en el Servicio de Hematología del Hospital General Docente "Dr. Juan Bruno Zayas Alfonso" de Santiago de Cuba, durante el quinquenio 2006-2011, para determinar las principales características clínicas y hematológicas en el momento del diagnóstico, así como la supervivencia global de los afectados, aunque los tratamientos administrados no tenían criterio curativo. La edad promedio de los ancianos fue de 70 años, en un rango etario de 60 a 90; en tanto, la variedad no linfoblástica representó 98,4 %, y todos los pacientes presentaron anemia y trombocitopenia como alteraciones hematológicas, con incremento en los requerimientos transfusionales. De igual forma, la presencia de blastos en la sangre periférica se demostró en 50 % y la hiperleucocitosis en 59,4 %, mientras las principales causas de muerte estuvieron relacionadas con la hemorragia cerebral y la progresión de la enfermedad con la infiltración multiorgánica, lo cual condujo a una supervivencia muy corta de los integrantes de la serie...


A descriptive and retrospective study of 64 patients older than 60 years with acute leukemia, assisted in the Hematology Service of "Dr. Juan Bruno Zayas Alfonso" Teaching General Hospital in Santiago de Cuba was carried out during the five year period 2006-2011, to determine the main clinical and hematological characteristics at the moment of diagnosis, as well as the global survival of those affected, although the administered treatments had no healing criterium. The average age of the elderly was 70 years, in an age range of 60 to 90; while the non lymphoblastic variety represented 98.4%, and all the patients presented anemia and thrombocytopenia hematological changes, with increment in the transfusional requirements. Likewise, the blastos presence in the peripheral blood was demonstrated in 50% and the hyperleucocytosis in 59.4%, while the main causes of death were related to the cerebral hemorrhage and the progression of the disease with the multiorganic infiltration, which led to a very short survival of the members of this series...


Assuntos
Leucemia , Leucemia/tratamento farmacológico , Idoso
10.
Acta gastroenterol. latinoam ; Acta gastroenterol. latinoam;38(2): 126-132, jun. 2008. tab
Artigo em Inglês | LILACS | ID: lil-503617

RESUMO

OBJECTIVE: this study aimed to determine the prevalence and characteristics of gastrointestinal manifestations on initial clinical presentation of acute leukemias (AL) in childhood. MATERIAL AND METHODS: this is a retrospective and descriptive study that assessed medical records of 354 patients with AL from January 1995 to December 2004. RESULTS: acute lymphoid leukemia (ALL) was diagnosed in 273 (77.1%) patients and acute non-lymphocytic leukemia (AML) in 81 (22.9%). There were 210 males (59.4%) and 144 females (40.6%). The most common presenting features were: abdominal pain (19.5% in ALL and 11.8% in AML), nausea and vomiting (14.9 in ALL and 14% in AML), abdominal distention (18.5 in ALL and 8.6% in AML; p 0.024), constipation (5% in ALL and 6.5% in AML), diarrhea (3.6% in ALL and 11.8% in AML; p 0.03%), and gastrointestinal bleeding (7.9% in ALL and 9.7% in AML). Ultrasound scanning was made in 61.1% and hepatomegaly was found on 33.6% and esplenomegaly on 28.5% of the patients with AL. Seventy-seven (21.7%) and 15 (4.2%) patients received nonsteroidal anti-inflammatory drugs and glucocorticoids before the diagnostic of AL. An association is well-defined between abdominal symptoms like nausea, vomiting and pain and use of this therapy but this association did not occurred clearly in this study. CONCLUSIONS: gastrointestinal symptoms are not very well-documented as initial manifestation of leukemia in children and should be considered on the differential diagnosis of gastrointestinal symptoms of unknown etiology in children.


Objetivo: el objetivo del estudio fue determinar la prevalencia y las características de las manifestaciones gastrointestinales en la presentación clínica inicial de las leucemias linfoides agudas (LLA) en la infancia. Materialy métodos: se trata de un estudio descriptivo y retrospectivo que evaluó los registros médicos de 354 pacientescon LLA de enero de 1995 a diciembre de 2004. Resultados: la (LLA) ha sido diagnosticada en 273 (77,1%) pacientes y leucemia mieloide aguda (LMA) en 81 (22,9%). Hubo 210 niños (59,4%) y 144 niñas (40,6%). Los síntomas más comunes de presentaciónhan sido los siguientes: dolor abdominal(19,5% en LLA y 11,8% en el LMA), náuseas y vómitos (14,9 en LLA y 14% en LMA, P 0.024), distensión abdominal (18,5 en LLA y 8,6% en LMA, p 0,024), estreñimiento (5% en LLA y 6,5% en LMA), diarrea (3,6% en LLA y 11,8% en LMA, p 0,03%) y hemorragia gastrointestinal (7,9% en LLA y 9,7% enLMA). La ecografía fue realizada en 61,1% de los pacientes encontrándose hepatomegalia en 33,6% y esplenomegalia en 28,5% con LLA. Setenta y siete (21,7%) y 15 (4,2%) pacientes recibieron los fármacos antiinflamatorios no esteroides y glucocorticoides antes del diagnóstico de LLA. Hay una asociación bien definidaentre síntomas abdominales como náuseas, vómitos y dolor y el uso de esta terapia pero esta asociación no seprodujo claramente en este estudio. Conclusiones: las manifestaciones gastrointestinales no están bien documentadas como manifestaciones iniciales de la leucemia en los niños y debe considerarse en el diagnóstico diferencial de los síntomas gastrointestinales de etiología desconocida en estas edades.


Assuntos
Humanos , Masculino , Feminino , Lactente , Pré-Escolar , Criança , Adolescente , Gastroenteropatias/etiologia , Leucemia Mieloide Aguda/complicações , Leucemia-Linfoma Linfoblástico de Células Precursoras/complicações , Estudos Retrospectivos , Leucemia Mieloide Aguda/sangue , Leucemia-Linfoma Linfoblástico de Células Precursoras/sangue
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA